Behandling af Boern Med Foedevareallergi Med Omalizumab (Xolair)
-
- STATUS
- Recruiting
-
- End date
- Feb 1, 2022
-
- participants needed
- 100
-
- sponsor
- Carsten Bindslev-Jensen
Summary
Food allergy is a common disease in childhood affecting up to 8% of children in Westernized countries. About 30 percent of children with food allergies are allergic to more than one food, most often milk, egg, wheat, peanut and tree nut. Peanut and hazelnut are common triggers of severe and potentially fatal food-induced anaphylactic reactions. Currently, there is no curative treatment for food allergy. Novel therapies for this potentially life-threatening condition are therefore much needed.
Description
Randomized, double-blind, placebo-controlled study to study the effect of Omalizumab on children with food allergy.
Primary endpoint: Change in challenge threshold after 3 months of treatment in patients treated with Omalizumab versus placebo.
Secondary endpoints: Change in challenge threshold at 6 months. Change in Skin Prick Test (SPT), serum markers for allergy (specific IgE, IgG4, BAT (basofil activation test)), severity of comorbidity, and quality of life from at 3 and 6 months. Change in treshold within and between the groups.
The investigator's hypothesis is that increased Omalizumab dose and/or a longer treatment period will increase food allergy threshold.
Within the groups:
- 3 months treatment with Omalizumab in asthma dose versus 6 months with Omalizumab in asthma dose - in primary responders
- 3 months treatment with Omalizumab in asthma dosing versus 3 months additional treatment with Omalizumab in max dose - in primary non-responders
- 3 months treatment with placebo versus 6 months with placebo- in primary placebo-responders
- 3 months treatment with placebo versus 3 months with max dose Omalizumab - placebo cross over to active.
Between the groups:
- 3 months treatment with Omalizumab in asthma dose versus 3 months with max dose Omalizumab
- 6 months treatment with Omalizumab in asthma dose versus 3 months with max dose Omalizumab.
Patients are randomized electronically via an e-CRF prepared by OPEN in RedCap. Assigned 3:1 to Omalizumab or placebo in 13 x 8 block (6:2) by a blinded health care person.
GCP-monitoring is performed by the local GCP-unit at Odense University Hospital
Details
| Condition | Food Allergy, food allergies |
|---|---|
| Treatment | Placebo, omalizumab |
| Clinical Study Identifier | NCT04037176 |
| Sponsor | Carsten Bindslev-Jensen |
| Last Modified on | 25 January 2021 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer